Yuhan Corporation Stock

Equities

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
77,400 KRW +4.59% Intraday chart for Yuhan Corporation +8.10% +12.50%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2,669B 1.97B Sales 2025 * 2,306B 1.71B Capitalization 5,767B 4.27B
Net income 2024 * 177B 131M Net income 2025 * 222B 164M EV / Sales 2024 * 2.07 x
Net cash position 2024 * 232B 172M Net cash position 2025 * 363B 269M EV / Sales 2025 * 2.34 x
P/E ratio 2024 *
36.5 x
P/E ratio 2025 *
28.7 x
Employees 1,999
Yield 2024 *
0.53%
Yield 2025 *
0.54%
Free-Float 67.3%
More Fundamentals * Assessed data
Dynamic Chart
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Progen Co., Ltd. announced that it has received KRW 9.71405799 billion in funding from Yuhan Corporation and other investors CI
COSON Co., Ltd. announced that it expects to receive KRW 3 billion in funding from Cruise Holdings Co., Ltd., Yuhan Corporation and other investors. CI
Yuhan Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million. CI
Contagion fears spread as China property sector cash crunch intensifies RE
Yuhan Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Country Garden shares dive after bond trading halted, fans further economic distress RE
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. CI
More news
1 day+4.59%
1 week+8.10%
Current month+6.91%
1 month+10.41%
3 months+23.64%
6 months+31.93%
Current year+12.50%
More quotes
1 week
69 600.00
Extreme 69600
77 500.00
1 month
69 600.00
Extreme 69600
77 500.00
Current year
57 500.00
Extreme 57500
83 400.00
1 year
52 285.71
Extreme 52285.7143
84 190.48
3 years
47 571.43
Extreme 47571.4286
84 190.48
5 years
30 851.34
Extreme 30851.3428
84 190.48
10 years
21 997.28
Extreme 21997.2793
84 190.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 87-04-30
Chairman 72 78-04-30
Director/Board Member 66 -
Members of the board TitleAgeSince
Chairman 72 78-04-30
Chief Executive Officer 69 87-04-30
Director/Board Member 66 -
More insiders
Date Price Change Volume
24-05-17 77,400 +4.59% 972,490
24-05-16 74,000 +5.87% 606,723
24-05-14 69,900 -0.99% 283,525
24-05-13 70,600 -1.40% 248,054
24-05-10 71,600 +0.14% 203,490

End-of-day quote Korea S.E., May 16, 2024

More quotes
Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
77,400 KRW
Average target price
87,419 KRW
Spread / Average Target
+12.94%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. A000100 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW